ArticleCost effectiveness and resource allocation : C/E2026
Cost-effectiveness analysis of a prognostic risk assessment for early-stage 1-3b diabetic kidney disease patients in the United States.
Jacie T Cooper et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.